Business
TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that it has entered into a definitive securities purchase agreement for the issuance and sale in a private placement of an aggregate of $12.5 million of shares of its common stock, for an aggregate of 4.6 million shares, together with warrants to purchase an equal number shares of common stock at an exercis
About this update from Tuhura Biosciences, Inc.
[{"type":"text","content":"Secures $12.5 million of commitments in a private offering","length":58,"tagName":"p","attribs":{}},{"type":"text","content":"Secures an additional $3.0 million through payment of cash exercise price of warrants","length":85,"tagName":"p","attribs":{}},{"type":"text","content":"Funding provides capital for:","length":29,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Initiation of planned Phase 3 accelerated approval trial of IFx-2.0 targeting 40% enrollment by 2-2025 year end","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"Acquisition of and initiating a Phase 2 trial in NPM1 mutated AML, a novel VISTA inhibiting antibody through closing of Kineta merger","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"Advancing first-in-class immune modulating bi-specific, and bi-functional Antibody Drug Conjugates (ADC) and Antibody Peptide Conjugates (APCs)","length":143,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":387,"olType":false},{"type":"text","content":"TAMPA, Fla., June 3, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that it has entered into a definitive securities purchase agreement for the issuance and sale in a private placement of an aggregate of $12.5 million of shares of its common stock, for an aggregate of 4.6 million shares, together with warrants to purchase an equal number shares of common stock at an exercise price of $3.3125 per warrant share. The securities in the offering were sold at a combined purchase price of $2.65 per share and accompanying warrant, which represents a fifteen percent (15%) discount to the NASDAQ closing price of the Company's common stock on June 2, 2025.","length":848,"tagName":"p"},{"type":"text","content":"Under the definitive agreement, approximately $9.0 million of the total offering amount will be purchased in four equal tranches based on the Company's achievement of certain milestones (the "Initial Funding Amount"), and the remaining $3.5 million is required to be purchased and funded by December 31, 2025. One-fourth of the Initial Funding Amount will be purchased and funded at the initial closing...